NexMed Announces Positive Results For US Anti-Fungal Trial
PR Newswire (press release), NY - Aug 25, 2005 announced positive results from its US Phase 1 clinical study of NM100060, its proprietary lacquer treatment for onychomycosis, commonly known as nail fungus.

Biomed rounds: Flaccid investor interest takes MacroChem down
Boston Mass High Tech,  USA - Sep 12, 2005 And lurking deep in those Lexington labs was always the IP ace in the hole: a lacquer for nail fungus. MacroChem wasn�t always under duress.